Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Combined With Cabozantinib in Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
NCT03635892Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2018
- Primary completion
- Aug 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, cabozantinib in non-clear cell renal cell carcinoma (nccRCC), sponsored by Memorial Sloan Kettering Cancer Center. Started Aug 2018; status: active, not recruiting.
02
Drugs
nivolumabcabozantinib
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on NCT03635892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03635892.